Step right up: A biotech may soon sell an experimental med to dying ALS patients under ‘Right to Try’

During the debate over the new Right to Try legislation, a number of critics raised the argument that some companies would try to cash in by selling experimental drugs with an undefined risk profile to desperate, dying patients.